Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

960
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
960
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

984
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
984
Chemical Synapses01:26

Chemical Synapses

8.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment.

Muscle & nerve·2024
Same author

The chatbot left us speechless.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2023
Same author

Bilateral Acute Hippocampal Ischemia in Two Patients Abusing Cocaine: What is the Outcome?

Cureus·2022
Same author

Managing Myasthenia Gravis with Eculizumab Monotherapy Through Pregnancy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2022
Same author

A Case of MuSK Myasthenia Gravis Presenting With Persistent Respiratory Insufficiency.

Journal of clinical neuromuscular disease·2021
Same author

Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation.

JCI insight·2021

Related Experiment Video

Updated: Jul 15, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

Disease-Based Prognostication: Myasthenia Gravis.

Jorge L Almodovar1, Anahit Mehrabyan1

  • 1Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Seminars in Neurology
|September 26, 2023
PubMed
Summary

This review provides a framework for predicting outcomes in myasthenia gravis (MG), an autoimmune disorder affecting neuromuscular junctions. It examines key factors like clinical type, age, and comorbidities to guide prognosis for individual patients.

More Related Videos

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.9K

Related Experiment Videos

Last Updated: Jul 15, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.4K
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.9K

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an acquired autoimmune disorder impacting neuromuscular junction transmission, leading to fluctuating skeletal muscle weakness.
  • Accurate neuroprognostication is crucial for managing MG patients and involves understanding disease natural history and treatment outcomes.

Approach:

  • This review synthesizes current knowledge to establish a prognostic framework for clinicians encountering new MG patients.
  • It systematically evaluates various factors influencing MG prognosis, including clinical presentation, demographics, immunological markers, and disease severity.

Key Points:

  • Clinical type, age of onset, and specific antibody status are significant prognostic indicators in MG.
  • Thymus pathology and the presence of other autoimmune comorbidities can also influence disease progression and outcome.
  • Disease severity at diagnosis and during the initial phase provides valuable insights into long-term prognosis.

Conclusions:

  • A comprehensive assessment of multiple factors is essential for accurate neuroprognostication in myasthenia gravis.
  • This framework aims to empower clinicians in predicting probable outcomes for individual MG patients, facilitating personalized treatment strategies.
  • Further research into the interplay of these prognostic factors will refine our ability to manage MG effectively.